Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Plaque-type psoriasis diagnosed \>= 6 months prior~* Plaque-type psoriasis covering at least 10% of total body surface areas~* Psoriasis area-and-severity index score of \>=12 at screening and baseline~* Considered by treating dermatologist to be a candidate for phototherapy or systemic treatment of psoriasis~* Women of childbearing potential and all men must agree to use adequate birth control measures throughout the trials and for 12 months following the last injection of study agent~* Have no history of latent or active tuberculosis (TB)~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis or drug-induced psoriasis~* Women who are pregnant or nursing, or men and women planning pregnancy while enrolled in the study~* Patients who have used any therapeutic agent targeted at reducing IL-12 or IL-23~* Patients who have had a Bacillus Calmette-Guerin (BCG) vaccination within the previous 12 months prior to screening~* Patients who have a history of chronic or recurrent infectious disease or who have or have had a serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months prior to screening~* Patients who have or ever have had a nontuberculous mycobacterial infection or opportunistic infection~* Patients known to be infected with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* Patients who have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease~* Patients with a malignancy or who have a history of malignancy (with the exception of certain skin cancers and pre-invasive cervical cancer)~* Patients participating in another trial using an investigational agent or procedure~* Systemic immunosuppressants within 4 weeks of the first administration of study agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I: Placebo (Type: PLACEBO_COMPARATOR): None
- Group II: Ustekinumab 45 mg (Type: EXPERIMENTAL): None
- Group III: Ustekinumab 90 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).